Three placebo-controlled phase 3 trials have evaluated the efficacy and safety of inclisiran. Inclisiran lowered low-density lipoprotein (LDL) cholesterol similarly across all ages with an acceptable safety profile . The efficacy and safety profile of inclisiran was generally similar in both sexes .
Prof. R. Scott Wright (Mayo Clinic, USA) presented the results of 2 pooled analyses evaluating the efficacy and safety of inclisiran according to age and sex, respectively. Both analyses included data from three phase 3 placebo-controlled trials:
- ORION-9 in patients with heterozygous familial hypercholesterolaemia (HeFH);
- ORION-10 in patients with atherosclerotic cardiovascular disease (ASCVD); and
- ORION-11 in patients with ASCVD or ASCVD risk equivalents.
In the first analysis, a total of 3,660 patients were categorised according to age: <65 yea...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Remote risk management programme effective and efficient Next Article
No CV benefit from omega 3 in high-risk patients »